UP Scan centre provides another patient’s report to 18-year-old, Gastroenterologist booked

Gonda: A case has been registered against a gastroenterologist, manager, radiologist, and other staff at a medical scan center in Gonda, Uttar Pradesh, for allegedly issuing a scan report belonging to another person. The doctor reportedly prescribed medication based on this incorrect report, endangering the life of a teenager.

Kotwali Nagar Station House Officer (SHO) Manoj Kumar Pathak said the case was registered on Wednesday on the order of a court following a complaint by a person named Mahesh Kumar.

The police reported that the doctor and the other involved were accused of allegedly defrauding an 18-year-old man and endangering his life through negligence.

According to the FIR, Mahesh Kumar alleged that the Hope Scanning Centre provided him with the scan report of another person instead of his son’s. Based on the other person’s report, the doctor prescribed medications, which he claimed endangered the life of the 18-year-old boy.

Also Read: Amputation of Newborn’s Leg- Gynaecologist, Paediatric surgeon slapped Rs 50 Lakh Compensation for negligence

The FIR further mentions that due to the unbearable stomach pain, Mahesh Kumar took his 18-year-old son Sakti to Dr Saran on 12th February 2024. The doctor ordered an MRCP (magnetic resonance cholangiopancreatography) scan at the Hope Scanning Centre. Upon reviewing the scan results, Dr Saran informed Kumar that while his son would eventually recover, the treatment would require time.

Through severe treatments, Shakti’s pain persisted so his father consulted Dr. Rajneesh Singh at PGI Lucknow on March 15.

After conducting similar tests there it was found that Shakti’s all the reports were normal. It was then revealed that all the previous scan reports from the Hope Scanning Centre were not Shakti’s but of another person named Ram Milan Goswami.

Following the discovery of his son’s reports, Mahesh Kumar again Contacted the Hope Scanning Center only to receive yet another report that was still incorrect. This led Kumar to allege that Dr Saran for prescribing the wrong medicines, which jeopardized Sakti’s health.

Pathak stated that since the incident took place before July 1 of this year, it has been registered under the IPC rather than the Bharatiya Nyaya Sanhita, which came into effect on that date.

Also Read: Medical Negligence during Cataract Surgery: Jaipur’s Eye Hospital, Doctor directed to pay Rs 16.6 Lakh Compensation

According to the PTI report, SHO Pathak said a case was registered on Wednesday on the court’s order under Indian Penal Code sections 420 (fraud) and 336 (negligently endangering life) and the investigation was handed over to sub-inspector Rajneesh Dwivedi.

However, the accused manager of the scan centre has claimed that the following allegations by Mahesh Kumar are baseless and the FIR has been lodged just for harassment.

Powered by WPeMatico

MKCG Medical College 2nd year MBBS students allege ragging by seniors, NMC intervenes

Berhampur: A second-year MBBS student of MKCG Medical College has brought allegations of ragging by seniors, prompting the authorities to launch an investigation into the matter. Meanwhile, the National Medical Commission (NMC) has taken cognisance of the complaints lodged by the parents of the victim students and has directed the Dean of the medical college to conduct a probe.

According to recent media reports, several second-year medical students have alleged that they were being ragged and harassed by seniors at the hostel. The student claimed that the ragging started when the first-year students shifted to a different hostel after completing their year. 

Following this, the second-year students were relocated from Cabin Block to three different hostels. After their relocation, the students claimed that the seniors harassed them mentally and physically.  

Also read- Ragging at MKCG Medical College: HC expresses Concern, orders Police Probe

When these students informed their parents about the issue, several complaints started pouring in at the desk of NMC. Taking cognizance of the parent’s complaints, the apex regulatory body asked the Dean of the medical college to initiate an investigation.

In response to the NMC letter, the college authorities formed an internal committee. It had already started an investigation into the allegations. As per a Prameya news report, a meeting of the Anti-Ragging Committee is expected to take place, where both second-year and senior students are mandatory to be present.

Showing cooperation with NMC, the college authorities have declared that they will take strict disciplinary action against those involved in the raging incidents if the allegations are true. 

The college principal, Professor Dr. Suchitra Das, told the daily, “Plans are going on to relocate the second-year students to a separate hostel for their safety and comfort.”

Medical Dialogues had reported a similar ragging incident at MKCG Medical College and Hospital. In February this year, two fourth-year MBBS students were suspended from attending classes and from staying in the hostel for two months after they were found guilty of ragging a junior medical student. 

Also read- 2 MBBS students of MKCG Medical College suspended for ragging junior

Powered by WPeMatico

Merck’s KEYTRUDA Gains European Approval for Two New Gynecologic Cancer Treatments

RAHWAY: Merck, also known as MSD outside the US and Canada, announced that the European Commission (EC) has approved two new indications for KEYTRUDA (pembrolizumab), its anti-PD-1 therapy, in gynecologic cancers.

The first approval is for use with carboplatin and paclitaxel as a first-line treatment for adults with primary advanced or recurrent endometrial carcinoma who are eligible for systemic therapy. The second approval is for KEYTRUDA combined with chemoradiotherapy (CRT) for adults with FIGO 2014 Stage III-IVA locally advanced cervical cancer who have not undergone prior definitive therapy.

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers—three for endometrial cancer and two for cervical cancer.

“These KEYTRUDA-based regimens have the potential to change the treatment paradigm for people with endometrial and cervical cancer, two of the most commonly diagnosed cancers among women in Europe,” said Dr Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.

“These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from earlier lines of therapy to treating advanced disease” the company stated.

The EC approvals are based on results from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868, and the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, respectively, and follow positive recommendations from the Committee for Medicinal Products for Human Use received in September 2024.
In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone.
In KEYNOTE-A18, KEYTRUDA in combination with concurrent CRT demonstrated statistically significant and clinically meaningful improvements in overall survival (OS) and PFS compared to concurrent CRT alone for newly diagnosed patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer.
These approvals allow marketing of these KEYTRUDA regimens for these indications in all 27 EU member states, as well as Iceland, Liechtenstein, Norway and Northern Ireland. Timing for commercial availability of KEYTRUDA for these indications in individual EU countries will depend on multiple factors, including the completion of national reimbursement procedures.
In June 2024, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, was approved in the U.S. for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma based on PFS results from the NRG-GY018 trial. The KEYTRUDA regimen reduced the risk of disease progression or death by 70% (HR=0.30 [95% CI, 0.19-0.48]; p<0.0001) in patients whose cancer was mismatch repair deficient (dMMR) and by 40% (HR=0.60 [95% CI, 0.46-0.78]; p<0.0001) in patients whose cancer was mismatch repair proficient (pMMR) compared to placebo with carboplatin and paclitaxel followed by placebo alone.
In January 2024, KEYTRUDA in combination with CRT was approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer based on PFS results from the KEYNOTE-A18 trial. The KEYTRUDA regimen reduced the risk of disease progression or death by 41% (HR=0.59 [95% CI, 0.43-0.82]) versus concurrent CRT alone for these patients.

Read also: Merck’s RSV antibody Clesrovimab for infants shows 60.4% effectiveness in mid-to-late stage clinical trial

Powered by WPeMatico

Health Bulletin 25/ October/ 2024

Here are the top health news for the day:

Gujarat medical council suspends two doctors following misconduct allegations
Taking action against two doctors from Rajkot and Ahmedabad, the Gujarat Medical Council (GMC) has barred them from practice for one year and six months respectively.
While one of these doctors has been found guilty of committing fraud in the Pradhan Mantri Jan Arogya Yojana (PMJAY) scheme, the other doctor, a Government employee, reportedly was absent at the clinic during a surprise visit of the Chief District Health Officer and another unidentified person was treating his patients.
For more information, click on the link below:
Chennai: Rainbow Hospital’s operations suspended after YouTuber posts video of cutting newborn’s umbilical cord
Taking action against Chennai-based Rainbow Hospitals for allowing a YouTuber inside the operation theatre and permitting him to cut the umbilical cord of his newborn baby and record it, the Health Department of Tamil Nadu has barred it from all patient care activities for 10 days.
Therefore, the hospital will not be allowed to do any patient-care activities including out-patient services, registration of new patients, conducting elective surgeries, or admitting patients for 10 days. The only exception has been granted to pregnant women who registered with the hospital and consulted doctors there. Such women can be taken to the hospital for deliveries.

For more information, click on the link below:

Chennai doctor arrested on charges of sexual harassment of woman
The Chief of Cardiac Electrophysiology and Pacing at the Madras Medical Mission has been arrested following allegations from a woman who claimed that the doctor sexually abused and harassed her while at the hospital.
According to the complaint, a woman employed at a hospital alleged that a doctor had been sexually abusing her since the start of her career there. This prompted her to report the incident to the National Commission for Women and the Chennai District Collector.

For more information, click on the link below:

Chennai doctor arrested for allegedly sexually harassing woman at hospital

Cardiac arrest during marathon: Fortis Cardiologist saves fellow runner’s life with CPR
During the Delhi half marathon this week at Jawaharlal Nehru Stadium, a cardiologist’s race turned into a life-saving mission. Dr. Ramit Wadhwa, a non-invasive cardiologist at Fortis Hospital, Gurugram, wasn’t just aiming to finish; he was about to save a life.
When a fellow runner collapsed mid-race, Dr Wadhwa sprang into action without hesitation. He administered CPR, a crucial intervention that helped stabilise the man before he was transferred to the nearest hospital.

Powered by WPeMatico

Examining the clinical significance of microvascular inflammation after kidney transplantation

Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024, from October 23–27.

Powered by WPeMatico

Advanced bladder cancer patients with alterations in FGFR3 gene respond well to investigational drug: Clinical trial

Patients with advanced bladder cancer that has spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug targets changes in the FGFR3 gene that drive tumor growth in about 10%-20% of these patients.

Powered by WPeMatico

Researchers discover key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors

Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs. The yet-to-be-published findings are presented on Friday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Powered by WPeMatico

New ‘mini-protein’ carries radiation dose directly to tumors without harming healthy tissues

Researchers have shown for the first time that it is possible for a specially designed ‘mini-protein’ to deliver a radiation dose directly to tumor cells expressing a protein on their cell surfaces called Nectin-4, which is often found in a number of different cancers.

Powered by WPeMatico

Scientists create digital twins of cancer patients to predict how well treatments may work

Researchers have shown that they can accurately recreate clinical trials of new treatments using “digital twins” of real cancer patients. The technology, called FarrSight-Twin, which is based on algorithms used by astrophysicists to discover black holes, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Powered by WPeMatico

Violence against Doctors: Punjab Govt doctors prepare for agitation over lack of security measures

Chandigarh: Witnessing a series of attacks and violence against doctors at government medical colleges and hospitals which has increased after the RG Kar incident, the the Punjab Civil Medical Services (PCMS) is on the verge of agitation. 

Despite receiving assurances from the AAP-led Punjab Government for enhanced security and implementation of the Dynamic Assured Career Progression (DACP) scheme, the doctors received no tangible action from the government. Therefore, the doctors are now planning to follow the path of agitation.

In the last two months, more than a dozen assaults have been reported at government health facilities across Punjab, most recently at the Civil Hospital in Jalandhar and the Community Health Centre (CHC) in Dhakoli while others are at Dera Baba Nanak, Patiala, Jagron, Sunam, Rajpura, Ferozepur and Naushera Majha Singh. 

Also read- Punjab doctors end strike after State Government’s assurance

On October 20, an intoxicated man assaulted a doctor on night duty and harassed a female colleague at Jalandhar’s civil hospital. That same night, two groups clashed at the community health centre (CHC) in Dhakoli, forcing a woman doctor and staff to lock themselves in a room for safety until police arrived.

After the intervention of the association in the incidents, the state police lodged the cases against the alleged accused under Bharatiya Nyaya Sanhita and the Punjab Protection Medicare Services Institutions (Prevention of Violence and Damage of Property) Act.

Speaking to TNIE, Dr Akhil Sarin, president of the Punjab Civil Medical Services (PCMS) Association of Punjab said, “If commitment made by the government is not met within the stipulated time frame then the doctors will be forced to follow the path of agitation. On October 21, a letter was written to the state health and family welfare secretary requesting a meeting regarding a review of the implementation of security provisions.”

“On September 11 the association met with the cabinet subcommittee and received a written assurance that a comprehensive security framed work at all the 24/7 centres of the state would be put in place within a week of the meeting and also the government agreed to the implementation of dynamic assured carrier progressions (DACPs) within 12 weeks of the meeting but nothing happened on the ground,’’ he added.

Medical Dialogues had earlier reported that a protest began on September 9 where the doctors suspended outpatient department services across all government facilities. However, the Punjab Civil Medical Services Association (PCMSA) called off its ongoing strike after the state government accepted their demand. 

“After the meeting, the state health minister announced and reiterated that the assurances will be implemented within the stipulated time frame. However even after the lapse of six weeks, no on-ground steps for implementation of the assurances are perceptible,” Dr Akhil added. 

Powered by WPeMatico